Safety and effectiveness of fecal microbiota transplantation for ulcerative colitis, Crohn's disease, and clostridium difficile infection.

Safety and effectiveness of fecal microbiota transplantation for ulcerative colitis, Crohn's disease, and clostridium difficile infection. - FMT for IBD and CDI

Status

Recruiting

Phases

Phase 1

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000020136

Enrollment

Registered

2015-12-10

Start date

2015-12-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis, Crohn&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)CDI recurrent or refractory CDI by vancomycin 2)IBD IBD not responded by conventional therapy including 5ASA, corticosteroid, and biologics

Exclusion criteria

Exclusion criteria: (1)Recipient 1)Allergy to drugs used in FMT 2)Pregnant or possible pregnant 3)Judged as unsuitable by researchers (2)Donor 1)Malignancy, active or choronic infection 2)pregnant 3)3)Judged as unsuitable by researchers

Design outcomes

Primary

Measure	Time frame
Adverse events of FMT, change of activity scores of patients with IBD and symptoms of patients with CDI by FMT	—

Secondary

Measure	Time frame
Change of gut microbiota by FMT	—

Countries

Japan

Contacts

Public ContactNaoki Ohmiya

Fujita Health University Department of Gastroenterology

shokakan@fujita-hu.ac.jp0562-93-9240

Outcome results